Extension Study of ABP-671 in Participants With Gout
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 580
- Registration Number
- NCT06276556
- Locations
- πΊπΈ
Alliance for Multispecialty Research, Tempe, Arizona, United States
πΊπΈTucson Neuroscience Research, LLC, Tucson, Arizona, United States
πΊπΈAnaheim Clinical Trials (Cenexel ACT), Anaheim, California, United States
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-02-14
- Target Recruit Count
- 126
- Registration Number
- NCT06258213
- Locations
- πΊπΈ
Worldwide Clinical Trials, San Antonio, Texas, United States
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
Phase 2
Active, not recruiting
- Conditions
- Gout
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 580
- Registration Number
- NCT05818085
- Locations
- πΊπΈ
Alliance for Multispecialty Research, Tempe, Arizona, United States
πΊπΈTucson Neuroscience Research, LLC, Tucson, Arizona, United States
πΊπΈAnaheim Clinical Trials (Cenexel ACT), Anaheim, California, United States
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2023-04-12
- Target Recruit Count
- 60
- Registration Number
- NCT04638543
- Locations
- π¦πΊ
Paratus - Canberra Clinic, Canberra, Australia
π¦πΊParatus - Central Coast Clinic, Kanwal, Australia
π¦πΊPeninsula Private Hospital, Kippa-Ring, Australia
Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2020-06-23
- Target Recruit Count
- 12
- Registration Number
- NCT04303039
- Locations
- πΊπΈ
Pharmaron CPC, Inc., Baltimore, Maryland, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2020-02-12
- Target Recruit Count
- 27
- Registration Number
- NCT04060173
- Locations
- πΊπΈ
Celerion, Tempe, Arizona, United States
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2020-07-29
- Target Recruit Count
- 32
- Registration Number
- NCT03906006
- Locations
- πΊπΈ
Celerion, Tempe, Arizona, United States